Back to search

Ireland· IE-PA-PA22835/003/001

Novistig 0.5 mg/ml + 2.5 mg/ml solution for injection

A glycopyrronium bromid product containing glycopyrronium bromide + neostigmine metilsulfate, registered in Ireland by Sintetica GmbH. The same ATC class is registered in 12 of our 19 countries.

ATC A03AB02

Checked against HPRA (Ireland) on

Informational only — not a medical device.

SOURCE REGISTER · IEHPRA (Ireland)normalisedNovistig 0.5 mg/ml + 2.5 mg/ml soluti…ATCA03AB02REGISTER NO.IE-PA-PA22835/003/001PACKS LISTED1CHECKEDSeptember 28, 2026

Where it is registered

Glycopyrronium bromid is registered in 12 of 19 countries.

Countries holding a registration under ATC A03AB02 (glycopyrronium bromid), each read from that country’s own register.

  • This record: Ireland, from HPRA (Ireland)
  • 7 of them publish a price we can compare per daily dose

Glycopyrronium bromid · ATC A03AB02

12 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

HPRA (Ireland)
Active substance
Glycopyrronium bromide + Neostigmine Metilsulfate
Manufacturer
Sintetica GmbH
Country
Ireland (IE)
ATC code
A03AB02
ATC class
Glycopyrronium bromid
Defined daily dose
3 mg, O
Reimbursed
Not published by this register
Source register
HPRA (Ireland)
Last checked
September 28, 2026

Packs & prices · 1

  • ie_pa_number
    PA22835/003/001

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Glycopyrronium bromid in 4 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All glycopyrronium bromid products

Authorised across Europe · EMA

The same active substance is authorised in 13 EEA countries. Names it is sold under:

  • Austria · Combistig
  • Belgium · Robinul-Neostigmine
  • Denmark · Copneg, Robinul-Neostigmin
  • Estonia · Glynex
  • Finland · Copneg, Glycostigmin
  • United Kingdom (Northern Ireland) · Glycopyrrolate And Neostigmine Metilsulfate Mercury Pharmaceuticals Ltd,, Glycopyrronium Bromide And Neostigmine Metilsulfate Martindale Pharmaceuticals
  • Croatia · Novistig
  • Hungary · Novistig
  • Luxembourg · Robinul-Neostigmine
  • Norway · Copneg, Robinul-Neostigmin
  • Poland · Novistig
  • Sweden · Copneg, Robinul
  • Slovenia · Novistig

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/e1596475-86c0-4677-a1b1-d25c0a335b7a
GET /v1/drugs/e1596475-86c0-4677-a1b1-d25c0a335b7a?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Solution for injection",
  "routes": [
    "Intravenous use"
  ],
  "source": "hpra",
  "atc_all": [
    "A03AB02"
  ],
  "strength": null,
  "pa_number": "PA22835/003/001",
  "substances": [
    "Glycopyrronium bromide",
    "Neostigmine Metilsulfate"
  ],
  "legal_basis": "Generic application (Article 10(1) of Directive No 2001/83/EC)",
  "market_info": "Not marketed",
  "authorised_at": "29/01/2021",
  "dispensing_status": "Product subject to prescription which may not be renewed (A)",
  "registration_status": "AU",
  "supply_legal_status": "Supply through pharmacies only",
  "interchangeable_code": null
}

See everything about glycopyrronium bromid.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.